NGENLA™ (somatrogon-ghla) is approved by the U.S. Food and Drug Administration as a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Growth hormone deficiency is a rare disease that affects one in 3,500 to 10,000 children that delays or restricts growth caused by genetic mutations or as a disease acquired after birth.
Market to consolidate from 7 daily treatments to 3 long-acting therapies
Estimated $5.5 billion market expected to expand by up to 12.3% annually due to better adherence to weekly treatment3
NGENLA™ approved in 40 markets worldwide for one in 3,500-10,0001,2 pediatric patients affected by GHD
Pfizer pursuing additional approvals for other indications
1. National Organization for Rare Disorders. Growth Hormone Deficiency. https://rarediseases.org/rare-diseases/growth-hormone-deficiency/
2. Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):47-52. doi:10.1097/MED.0b13e32834ec952.
3. “Human Growth Hormone Market Size,” Grand View Research, Grand View Research, https://www.grandviewresearch.com/industry-analysis/human-growth-hormone-drugs-market
Adult growth hormone deficiency (AGHD) afflicts approximately 50,000 people in the U.S. There are two main causes: damage or trauma to the pituitary or hypothalamus gland, and being born with a growth hormone deficiency (GHD). Whereas growth hormone (GH) is principally used to assist growth in children, GH is necessary for GHD patients to maintain muscle, bone and fat tissues in a healthy balance and quality of life. Through our partnership with Pfizer, NGENLA’s potential to treat adult patients and related pediatric conditions is also under exploration.
See our pipeline